首页> 外文期刊>Expert opinion on investigational drugs >The farnesoid X receptor: a novel drug target?
【24h】

The farnesoid X receptor: a novel drug target?

机译:法尼醇X受体:新型药物靶标?

获取原文
获取原文并翻译 | 示例
       

摘要

Bile acids are end products of cholesterol metabolism. They are exclusively synthesised by the liver and subsequently secreted via the bile duct into the intestine to facilitate the absorption of dietary fat and fat-soluble vitamins. Nuclear receptors are ligand-activated transcription factors. The farnesoid X receptor (FXR) has recently been identified as a bile acid-activated nuclear receptor. FXR controls bile-acid synthesis, conjugation and transport, as well as lipid metabolism. Recent advances in FXR biology demonstrate that FXR may represent a valuable target for the identification of novel drugs to treat dyslipidaemia and cholestasis. However, for therapeutic purposes the development of selective FXR modulators, which only activate or inhibit specific FXR target genes and as such induce specific responses, will be required.
机译:胆汁酸是胆固醇代谢的最终产物。它们仅由肝脏合成,然后通过胆管分泌到肠中,以促进膳食脂肪和脂溶性维生素的吸收。核受体是配体激活的转录因子。法尼醇X受体(FXR)最近被鉴定为胆汁酸激活的核受体。 FXR控制胆汁酸的合成,结合和运输以及脂质代谢。 FXR生物学的最新进展表明,FXR可能是鉴定治疗血脂异常和胆汁淤积的新药的重要目标。然而,出于治疗目的,将需要开发仅激活或抑制特异性FXR靶基因并因此诱导特异性应答的选择性FXR调节剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号